LENZ Therapeutics (LENZ) Net Margin (2025 - 2026)
LENZ Therapeutics' (LENZ) quarterly Net Margin came in at 2220.25% in Q1 2026, down 873.15% on a QoQ basis from 287.17% in Q4 2025.
LENZ Therapeutics (LENZ) Net Margin (2025 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has 2 years of Net Margin data on file, last reported at 2220.25% in Q1 2026.
- On a quarterly basis, Net Margin changed N/A year-over-year to 2220.25% in Q1 2026; TTM through Mar 2026 was 1589.84%, a N/A change from a year earlier, with the FY2025 full-year figure at 1642.54%, changed N/A from the prior year.
- Net Margin for Q1 2026 stood at 2220.25%, down from 287.17% in the prior quarter.
- Over the last five years, Net Margin for LENZ reached as high as 287.17% in Q4 2025 and fell as low as 2220.25% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | LENZ Therapeutics | 158.34 Mn | 158.34 Mn | 825,000.00 | -2,220.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,220.25% |
| Dec 31, 2025 | 287.17% |
| Sep 30, 2025 | -133.60% |
| Jun 30, 2025 | -298.24% |